Global Retina Health Market Overview:
According to SPER Market Research, the Global Retina Health Market is estimated to reach USD 21.59 billion by 2032 with a CAGR of 7.8%.
To create electrical signals from the light that enters the eye, the retina—a tiny layer situated at the back of the eyes—must first convert the light into those signals. Images are created by the brain after it has processed the impulses. A Healthy retina can help avoid blindness as well as several visual problems and impairments. The two most common retinal diseases, macular degeneration and diabetic retinopathy impact millions of people globally. A wide range of treatments and medications are available to guarantee optimal retina Health, and as more people become aware of these options, the market for these products will grow gradually in the years to come.
Impact of COVID-19 on the Global Retina Health Market
The huge impact of COVID-19 pandemic has had several negative effects on people's Health all across the world. A substantial social and economic burden has been placed on individuals all across the world as a result of the aftermath. While big politicians are putting new frameworks into place and companies are embracing cutting-edge expansion methods to stay relevant, people are dealing with a variety of emotional anguish. The increase in instances has exacerbated emotional and financial problems, particularly for the elderly. The younger population has also been experiencing difficulties as a result of job losses and is choosing family care to deal with the effects. The development of a vaccine for COVID-19 is the main area of concentration, which diverts attention from other diseases.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2032 |
| Base year considered | 2021 |
| Forecast period | 2022-2032 |
| Segments covered | By Disease Indication, By Treatment, By Distribution Channel |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Companies Covered | Allergan
PLC, Applied Genetic
Technologies Corporation, Gensight Biologics, Hemera Biosciences LLC, Meiragtx
Ltd., Novartis AG, Oxford Biomedica PLC, Regenxbio Inc., Santen Pharmaceuticals Inc., Spark Therapeutics Inc.
|
Global Retina Health Market Segmentation:
By Disease Indication: Based on the Disease Indication, Global Retina Health Market is segmented as; Age-Related Macular Degeneration, Diabetic Retinopathy, Diabetic Retinopathy, Inherited Retinal Diseases, Retinoblastoma, Retinal Vein Occlusion, Others.
By Treatment: Based on the Treatment, Global Retina Health Market is segmented as; Drugs, Therapy, Gene Therapy, Nutrition Therapy, Surgery, others.
By Distribution Channel: Based on the Distribution Channel, Global Retina Health Market is segmented as; Hospital Pharmacy, Retail Pharmacy, Others.
By Region: The North American retina Health market is anticipated to expand quickly due to a variety of driving factors, including the high incidence of retinal diseases and the development of key market companies in the region. Due to the rapidly expanding Healthcare infrastructure and growing per capita income, the Asia-Pacific retina Health market will also experience significant expansion. A substantial senior population and increased public awareness of eye Health will also contribute to the market expanding at a strong rate.
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Retina Health Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Global Retina Health Market, By Disease Indication, 2019-2032 (USD Million)
6.1. Age-Related Macular Degeneration
6.2. Diabetic Retinopathy
6.3. Diabetic Retinopathy
6.4. Inherited Retinal Diseases
6.5. Retinoblastoma
6.6. Retinal Vein Occlusion
6.7. Others
7. Global Retina Health Market, By Treatment, 2019-2032 (USD Million)
7.1. Drugs
7.2. Therapy
7.3. Gene Therapy
7.4. Nutrition Therapy
7.5. Surgery
7.6. others
8. Global Retina Health Market, By Distribution Channel, 2019-2032 (USD Million)
8.1. Hospital Pharmacy
8.2. Retail Pharmacy
8.3. Others
9. Global Retina Health Market, By Region, 2019-2032 (USD Million)
9.1 North America
9.1.1 United States
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 Germany
9.2.2 United Kingdom
9.2.3 France
9.2.4 Italy
9.2.5 Spain
9.2.6 Rest of Europe
9.3 Asia-Pacific
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 Australia
9.3.5 South Korea
9.3.6 Rest of Asia-Pacific
9.4 South America
9.4.1 Brazil
9.4.2 Argentina
9.4.3 Rest of South America
9.5 Middle East & Africa
9.5.1 Kingdom of Saudi Arabia
9.5.2 United Arab Emirates
9.5.3 Rest of Middle East & Africa
10. Company Profiles
10.1 Allergan PLC
10.1.1 Company details
10.1.2 Financial outlook
10.1.3 Product summary
10.1.4 Recent developments
10.2 Applied Genetic Technologies Corporation
10.2.1 Company details
10.2.2 Financial outlook
10.2.3 Product summary
10.2.4 Recent developments
10.3 Gensight Biologics
10.3.1 Company details
10.3.2 Financial outlook
10.3.3 Product summary
10.3.4 Recent developments
10.4 Hemera Biosciences LLC
10.4.1 Company details
10.4.2 Financial outlook
10.4.3 Product summary
10.4.4 Recent developments
10.5 Mejragtx Ltd.10.5.1 Company details
10.5.2 Financial outlook
10.5.3 Product summary
10.5.4 Recent developments
10.6 Novaritis AG
10.6.1 Company details
10.6.2 Financial outlook
10.6.3 Product summary
10.6.4 Recent developments
10.7 Oxford Biomedica PLC
10.7.1 Company details
10.7.2 Financial outlook
10.7.3 Product summary
10.7.4 Recent developments
10.8 Regenxbio Inc.
10.8.1 Company details
10.8.2 Financial outlook
10.8.3 Product summary
10.8.4 Recent developments
10.9 Santen Pharmaceutical Inc.
10.9.1 Company details
10.9.2 Financial outlook
10.9.3 Product summary
10.9.4 Recent developments
10.10 Spark Therapeutics Inc.
10.10.1 Company details
10.10.2 Financial outlook
10.10.3 Product summary
10.10.4 Recent developments
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
